Researchers at St. Jude Children's Research Hospital have discovered a mechanism that controls a key protein linked to the cell's response to stress - a finding that holds promise for new ways to enhance cancer therapies or protect cells from dying after exposure to damaging chemicals or radiation.

The gene for this protein, called p53, is the most commonly mutated gene in human cancer; and it plays a critical role in helping cells respond to stress, especially stresses that damage DNA, according to researchers.

Previously, the rise in the level of p53 in cells whose DNA had been damaged was thought to be due only to a decrease in the rate at which the p53 protein is broken down in the cell.

The St. Jude study showed that the level of p53 protein synthesis increases following DNA damage.

This discovery suggests that researchers can use this newly recognized mechanism to modulate p53 function in the cell in order to control whether cells in the body mutate, and whether cells live or die after DNA damage.

A report is published in the journal Cell.

If a cell has been damaged, p53 protects the body by either preventing that cell from dividing or triggering a cascade of molecular signals that causes that cell to commit suicide¡ªa process called apoptosis. In this way, p53 rids the body of useless cells and prevents cells with potentially cancer-causing mutations from multiplying and spreading. Failure of a cell to activate p53 function after DNA damage can contribute to the generation of genetically altered cells that leads to cancer.

The St. Jude team showed that the competing proteins, ribosomal protein L26 ( RPL26 ) and nucleolin, vie for control of the messenger RNA ( mRNA ) that codes for p53.

Researchers identified a region of the mRNA that serves as a control switch for this process.
In undamaged cells, nucleolin binds to this region of p53 mRNA and suppresses synthesis. But after DNA damage, RPL26 binds to this region and increases the translation of the mRNA into the p53 protein.

If the researchers inhibited production of RPL26 in human cells that had been exposed to DNA damaging agents, like ionizing irradiation, the cells with damaged DNA failed to increase p53 protein, and thus failed to stop growing or failed to die as they should have. This demonstrated that RPL26 production is a critical player in the cell's response to DNA damage. In contrast, when the researchers reduced the levels of nucleolin in cells, p53 production after DNA damage increased.

" Our findings suggest that RPL26 and nucleolin play critical roles in controlling the production of p53 and the response of the cell to ionizing radiation and other types of cellular stress," said Michael Kastan, director of the St. Jude Cancer Center." Now we would like to use these new insights to develop ways to modulate RPL26 or nucleolin in order to alter p53 function in cells of the body. The ability to increase p53 function in tumor cells could increase the effectiveness of radiation and chemotherapy in treating certain types of tumors."

" On the other hand, these insights provide a potentially novel way to try to decrease levels of p53 so that we could protect cells in normal tissues from dying after exposure to toxins or oxidative damage," he added.

The discovery of the roles of RPL26 and nucleolin in p53 production may have much broader implications than just the regulation of p53 levels in response to DNA damage, according to Kastan.

Hypoxia and high doses of certain DNA-damaging agents inflict serious stress on cells, causing a general suppression of protein production, Kastan noted.
In order to cope with such stress, cells must maintain adequate levels of certain proteins. Therefore, the cell must be able to activate specific mechanisms in response to stress, even when protein production as a whole is being suppressed.
The binding of RPL26 to the 5¡äUTR appears to be an example of such a mechanism that bypasses the cell's usual shut-down of protein synthesis during times of stress, Kastan said.

Source: St. Jude Children's Research Hospital, 2005


XagenaMedicine2005